title: Cytarabine-induced neurotoxicity responding to methyl prednisolone.
authors.forename: Pankaj
authors.initials: P
authors.lastname: Malhotra
authors.forename: Sushil
authors.initials: S
authors.lastname: Mahi
authors.forename: Vivek
authors.initials: V
authors.lastname: Lal
authors.forename: Savita
authors.initials: S
authors.lastname: Kumari
authors.forename: Sanjay
authors.initials: S
authors.lastname: Jain
authors.forename: Subhash
authors.initials: S
authors.lastname: Varma
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D003561:Cytarabine / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D020258:Neurotoxicity Syndromes / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D008775:Methylprednisolone